NCT00786825

Brief Summary

The long-range goal of this project is to determine the effects of diabetes and the hypoglycemic consequences of intensive therapy on in vivo brain glucose metabolism in humans. We will measure brain glycogen turnover and content in normal controls and subjects with diabetes under conditions of modest hyper-and hypoglycemia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Dec 2004

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2004

Completed
3.9 years until next milestone

First Submitted

Initial submission to the registry

November 5, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 6, 2008

Completed
9.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
2 years until next milestone

Results Posted

Study results publicly available

December 18, 2019

Completed
Last Updated

December 18, 2019

Status Verified

December 1, 2019

Enrollment Period

13 years

First QC Date

November 5, 2008

Results QC Date

November 7, 2019

Last Update Submit

December 5, 2019

Conditions

Keywords

Type 1 diabetesHypoglycemia unawareness

Outcome Measures

Primary Outcomes (1)

  • Brain Glycogen Turnover Rate

    1 month

Study Arms (2)

somatostatin

EXPERIMENTAL

Type 1 diabetes and Hypoglycemia unawareness

Drug: somatostatin

2

NO INTERVENTION

Healthy control subjects

Interventions

Somatostatin may be used to suppress endogenous insulin secretion

somatostatin

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-65
  • Healthy control
  • Must be able to provide informed consent
  • Type 1 diabetes with hypoglycemia unawareness with hemoglobin A1c \< 7.5%
  • Poorly controlled diabetics with hemoglobin A1c \> 7.5%
  • Subjects with hypoglycemia unawareness must report an inability to recognize at least some blood glucose values \<58 mg/dL during the 3 months prior to the study.

You may not qualify if:

  • Over 300 pounds
  • Claustrophobic
  • History of ischemic heart disease, arrhythmia, of seizure disorder
  • Pregnant
  • On medications known to alter blood flow or carbohydrate metabolism
  • Have internally located pieces of metal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Minnesota

Minneapolis, Minnesota, 55414, United States

Location

Related Publications (1)

  • Seaquist ER, Moheet A, Kumar A, Deelchand DK, Terpstra M, Kubisiak K, Eberly LE, Henry PG, Joers JM, Oz G. Hypothalamic Glucose Transport in Humans During Experimentally Induced Hypoglycemia-Associated Autonomic Failure. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3571-3580. doi: 10.1210/jc.2017-00477.

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Interventions

Somatostatin

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Pituitary Hormone Release Inhibiting HormonesHypothalamic HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPancreatic HormonesNeuropeptidesPeptidesAmino Acids, Peptides, and ProteinsNerve Tissue ProteinsProteins

Results Point of Contact

Title
Elizabeth Seaquist, MD
Organization
University of Minnesota

Study Officials

  • Elizabeth R Seaquist, MD

    University of Minnesota

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 5, 2008

First Posted

November 6, 2008

Study Start

December 1, 2004

Primary Completion

December 1, 2017

Study Completion

December 1, 2017

Last Updated

December 18, 2019

Results First Posted

December 18, 2019

Record last verified: 2019-12

Locations